Research progress on the role of PD-1/PD-L1 pathway in autoimmune eye diseases

doi:10.3969/j.issn.1674-8115.2022.01.016

Abstract

Abstract:

Autoimmune eye diseases are a kind of inflammatory eye disease caused by autoimmune reaction, mainly including autoimmune uveitis, thyroid-associated ophthalmopathy, Sj?gren's syndrome-related ophthalmoxerosis, neuromyelitis optica spectrum disorder and so on. The pathogenesis of these diseases is complex, involving the ocular surface, intraocular and orbital lesions. Traditional treatment methods mainly include corticosteroids and immune inhibitors, which have low efficiency and many side effects. Therefore, more in-depth research on the pathogenesis of autoimmune eye diseases is needed in order to find therapeutic targets for the etiological treatment. Programmed death 1 (PD-1) has been confirmed to be associated with many autoimmune diseases, and PD-1/programmed death ligand 1 (PD-L1) pathway plays a key role in the regulation of immune responses. Inactivation of the PD-1/PD-L1 pathway may lead to abnormal activation of autoimmune T cells, leading to the occurrence and development of autoimmune diseases. In this review, the immune regulation mechanism of PD-1/PD-L1 pathway that has been discovered at the present stage, as well as its role in autoimmune ophthalmopathy, is systematically summarized, and the potential of targeted treatment of autoimmune eye diseases in the future is prospected.

Key words: autoimmune eye disease, programmed death 1 (PD-1), programmed death ligand 1 (PD-L1), autoimmune uveitis, thyroid-associated ophthalmopathy, Sj?gren's syndrome, neuromyelitis optica spectrum disorder

CLC Number:

Chenling YANG, Huifang ZHOU. Research progress on the role of PD-1/PD-L1 pathway in autoimmune eye diseases[J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2022, 42(1): 107-112.

TrendMD

References 50

1	LOHMANN T, LESLIE R D, LONDEI M. T cell clones to epitopes of glutamic acid decarboxylase 65 raised from normal subjects and patients with insulin-dependent diabetes[J]. J Autoimmun, 1996, 9(3): 385-389.
2	SCHWARTZ R H, MUELLER D L, JENKINS M K, et al. T-cell clonal anergy[J]. Cold Spring Harb Symp Quant Biol, 1989, 54 Pt 2: 605-610.
3	SHARPE A H. Mechanisms of costimulation[J]. Immunol Rev, 2009, 229(1): 5-11.
4	LAFFERTY K J, CUNNINGHAM A J. A new analysis of allogeneic interactions[J]. Aust J Exp Biol Med Sci, 1975, 53(1): 27-42.
5	EDNER N M, CARLESSO G, RUSH J S, et al. Targeting co-stimulatory molecules in autoimmune disease[J]. Nat Rev Drug Discov, 2020, 19(12): 860-883.
6	KEIR M E, BUTTE M J, FREEMAN G J, et al. PD-1 and its ligands in tolerance and immunity[J]. Annu Rev Immunol, 2008, 26: 677-704.
7	DONG H, STROME S E, SALOMAO D R, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion[J]. Nat Med, 2002, 8(8): 793-800.
8	YU J X, HODGE J P, OLIVA C, et al. Trends in clinical development for PD-1/PD-L1 inhibitors[J]. Nat Rev Drug Discov, 2020, 19(3): 163-164.
9	DAI S, JIA R, ZHANG X, et al. The PD-1/PD-Ls pathway and autoimmune diseases[J]. Cell Immunol, 2014, 290(1): 72-79.
10	KOBAYASHI M, KAWANO S, HATACHI S, et al. Enhanced expression of programmed death-1 (PD-1)/PD-L1 in salivary glands of patients with Sjögren's syndrome[J]. J Rheumatol, 2005, 32(11): 2156-2163.
11	RILEY J L. PD-1 signaling in primary T cells[J]. Immunol Rev, 2009, 229(1): 114-125.
12	SUN C, MEZZADRA R, SCHUNACHER T N. Regulation and function of the PD-L1 checkpoint[J]. Immunity, 2018, 48(3): 434-452.
13	BUTTE M J, KEIR M E, PHAMDUY T B, et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses[J]. Immunity, 2007, 27(1): 111-122.
14	SALMANINEJAD A, KHORAMSHIHI V, AZANI A, et al. PD-1 and cancer: molecular mechanisms and polymorphisms[J]. Immunogenetics, 2018, 70(2): 73-86.
15	FRANCISCO L M, SALINAS V H, BROWN K E, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells[J]. J Exp Med, 2009, 206(13): 3015-3029.
16	CHEN J, JIANG C C, JIN L, et al. Regulation of PD-L1: a novel role of pro-survival signalling in cancer[J]. Ann Oncol, 2016, 27(3): 409-416.
17	PRADHAN R, SINGHVI G, DUBEY SK, et al. MAPK pathway: a potential target for the treatment of non-small-cell lung carcinoma[J]. Future Med Chem, 2019, 11(8): 793-795.
18	DHILLON A S, HAGAN S, RATH O, et al. MAP kinase signalling pathways in cancer[J]. Oncogene, 2007, 26(22): 3279-3290.
19	LIU S, CHEN S, YUAN W, et al. PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways[J]. Oncotarget, 2017, 8(59): 99901-99912.
20	STUTVOET T S, KOL A, DE VRIES E G, et al. MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells[J]. J Pathol, 2019, 249(1): 52-64.
21	FREEMAN G J, LONG A J, IWAI Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation[J]. J Exp Med, 2000, 192(7): 1027-1034.
22	CARTER L, FOUSER L A, JUSSIF J, et al. PD-1:PD-L inhibitory pathway affects both CD4⁺ and CD8⁺ T cells and is overcome by IL-2[J]. Eur J Immunol, 2002, 32(3): 634-643.
23	杨培增. 临床葡萄膜炎[M]. 北京: 人民卫生出版社, 2004.
24	CHONG W P, HORAI R, MATTAPALLIL M J, et al. IL-27p28 inhibits central nervous system autoimmunity by concurrently antagonizing Th1 and Th17 responses[J]. J Autoimmun, 2014, 50: 12-22.
25	HORAI R, ZÁRATE-BLADÉS C R, DILLENBURG-PILLA P, et al. Microbiota-dependent activation of an autoreactive T cell receptor provokes autoimmunity in an immunologically privileged site[J]. Immunity, 2015, 43(2): 343-353.
26	HUANG Y, FANG S, LI D, et al. The involvement of T cell pathogenesis in thyroid-associated ophthalmopathy[J]. Eye (Lond), 2019, 33(2): 176-182.
27	ZHONG Z, SU G, KIJLSTRA A, et al. Activation of the interleukin-23/interleukin-17 signalling pathway in autoinflammatory and autoimmune uveitis[J]. Prog Retin Eye Res, 2021, 80: 100866.
28	MENG Q, YANG P, GUO H, et al. Characteristic expression of PD-1 and its ligands mRNAs in patients with noninfectious uveitis[J]. Int J Clin Exp Med, 2016, 9(1): 323-329.
29	CHEN J, QIAN H, HORAI R, et al. Mouse models of experimental autoimmune uveitis: comparative analysis of adjuvant-induced vs spontaneous models of uveitis[J]. Curr Mol Med, 2015, 15(6): 550-557.
30	LEE D J, TAYLOR A W. Recovery from experimental autoimmune uveitis promotes induction of antiuveitic inducible Tregs[J]. J Leukoc Biol, 2015, 97(6): 1101-1109.
31	ALGAZI A P, TSAI K K, SHOUSHTARI A N, et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies[J]. Cancer, 2016, 122(21): 3344-3353.
32	MATSUO T, YAMASAKI O. Vogt-Koyanagi-Harada disease-like posterior uveitis in the course of nivolumab (anti-PD-1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma[J]. Clin Case Rep, 2017, 5(5): 694-700.
33	SUN M M, LEVINSON R D, FILIPOWICZ A, et al. Uveitis in patients treated with CTLA-4 and PD-1 checkpoint blockade inhibition[J]. Ocul Immunol Inflamm, 2020, 28(2): 217-227.
34	HIROMATSU Y, EGUCHI H, TANI J, et al. Graves' ophthalmopathy: epidemiology and natural history[J]. Intern Med, 2014, 53(5): 353-360.
35	FANG S, LU Y, HUANG Y, et al. Mechanisms that underly T cell immunity in Graves' orbitopathy[J]. Front Endocrinol (Lausanne), 2021, 12: 648732.
36	夏晓玲. 甲状腺相关性眼病患者外周血CD4⁺、CD8⁺ T细胞表面PD-1表达水平的改变及其临床意义[D]. 上海: 第二军医大学, 2016.
37	BETTELLI E, CARRIER Y, GAO W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells[J]. Nature, 2006, 441(7090): 235-238.
38	GONZÁLEZ-AMARO R, MARAZUELA M. T regulatory (Treg) and T helper 17 (Th17) lymphocytes in thyroid autoimmunity[J]. Endocrine, 2016, 52(1): 30-38.
39	SYN N L, TENG M W L, MOK T S K, et al. De-novo and acquired resistance to immune checkpoint targeting[J]. Lancet Oncol, 2017, 18(12): e731-e741.
40	YAZICI B, YAZICI Z, YALÇINKAYA U. Aneurysmal bone cyst secondary to ossifying fibroma in the orbit[J]. Ophthalmic Plast Reconstr Surg, 2011, 27(4): e84-e85.
41	SAGIV O, KANDL T J, THAKAR S D, et al. Extraocular muscle enlargement and thyroid eye disease-like orbital inflammation associated with immune checkpoint inhibitor therapy in cancer patients[J]. Ophthalmic Plast Reconstr Surg, 2019, 35(1): 50-52.
42	王鑫, 刘苏. 干燥综合征相关型干眼症的临床诊疗进展[J]. 中华眼科医学杂志(电子版), 2018, 8(2): 82-86.
43	杨月, 侯佳奇, 李国陵, 等. PD-1及其配体在原发性干燥综合征患者唇腺中的表达及临床意义[J]. 临床与病理杂志, 2017, 37(3): 456-461.
44	CHIHARA N, ARANAMI T, SATO W, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica[J]. Proc Natl Acad Sci U S A, 2011, 108(9): 3701-3706.
45	VARRIN-DOYER M, SPENCER C M, SCHULZE-TOPPHOFF U, et al. Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter[J]. Ann Neurol, 2012, 72(1): 53-64.
46	XUE Q, LI X, GU Y, et al. Unbalanced expression of ICOS and PD-1 in patients with neuromyelitis optica spectrum disorder[J]. Sci Rep, 2019, 9(1): 14130.
47	WAN B, NIE H, LIU A, et al. Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis[J]. J Immunol, 2006, 177(12): 8844-8850.
48	FANG S, HUANG Y, ZHONG S, et al. Regulation of orbital fibrosis and adipogenesis by pathogenic Th17 cells in Graves orbitopathy[J]. J Clin Endocrinol Metab, 2017, 102(11): 4273-4283.
49	LI X, ZHONG T, TANG R, et al. PD-1 and PD-L1 expression in peripheral CD4/CD8⁺ T cells is restored in the partial remission phase in type 1 diabetes[J]. J Clin Endocrinol Metab, 2020, 105(6): 1947-1956.
50	RAPTOPOULOU A P, BERTSIAS G, MAKRYGIANNAKIS D, et al. The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis[J]. Arthritis Rheum, 2010, 62(7): 1870-1880.

[1]	Rou SUN, Hui-fang ZHOU. Research progress of endoscope-assisted transnasal orbital decompression [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(12): 1692-1697.
[2]	WU Yu, LU Yi, SUN Rou, ZHANG Shuo, SUN Jing, ZHOU Hui-fang, FAN Xian-qun. Expression and clinical significance of α1-antitrypsin in thyroid-associated ophthalmopathy [J]. , 2020, 40(4): 430-.
[3]	HUANG Xin-xin1, DING Jie2, HAN Lu2, YU Lu1, ZHU De-sheng2, GUAN Yang-tai1, 2. Correlation between blood-brain barrier permeability and physical disability in patients with neuromyelitis optica spectrum disorders [J]. , 2018, 38(5): 520-.
[4]	SUN Jing, ZHANG Yi-dan, LIU Xing-tong, ZHONG Si-si, WANG Yang, ZHOU Hui-fang#, FAN Xian-qun#. Modified levator lengthening for thyroid-associated ophthalmopathy related upper eyelid retraction [J]. , 2017, 37(6): 764-.
[5]	ZHANG Yi-dan, FAN Xian-qun, ZHOU Hui-fang. Research progress of orbital decompression for the treatment of thyroid-associated ophthalmopathy [J]. , 2016, 36(09): 1383-.
[6]	YU Qi, XU Xun. Research progress of animal models of experimental autoimmune uveitis [J]. , 2013, 33(10): 1411-.